Literature DB >> 6852923

Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.

H Snippe, A J van Houte, J E van Dam, M J De Reuver, M Jansze, J M Willers.   

Abstract

Hexasaccharide (HS) containing 3 U of cellobiuronic acid was isolated from Streptococcus pneumoniae type 3 capsular polysaccharide S3 and coupled to bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or tetanus toxoid (TT). The immunogenicity of these HS-protein conjugates in BALB/c mice was studied by measuring the production of circulating antibodies and the induction of protective immunity to viable S. pneumoniae type 3. Immunization of BALB/c mice with 0.5 micrograms of S3 resulted in the induction of immunoglobulin M (IgM) antibodies and complete protection against 25 U of a mean lethal dose of S. pneumoniae type 3 for 19 weeks after immunization. BALB/c mice immunized with 100 micrograms of HS9-BSA (containing 12 micrograms of HS) were also protected due to circulating IgM antibodies. Repeated injections with either 100 micrograms of HS9-BSA (three immunizations) or 100 micrograms of HS6-KLH (two immunizations) resulted in high levels of circulating IgG antibodies. These HS-protein conjugates induced complete protection which lasted at least 14 (HS9-BSA), 23 (HS6-KLH), or 8 (HS16-TT) weeks after the last immunization. Protection against viable S. pneumoniae type 3 could be passively transferred to nonimmunized mice by antisera containing IgM or IgG antibodies or both. Sera containing both IgM and IgG antibodies gave better protection than sera containing only IgM antibodies. The specificity of the induced protection was confirmed by challenge with the non-cross-reacting S. pneumoniae type 11.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852923      PMCID: PMC348130          DOI: 10.1128/iai.40.3.856-861.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

Review 1.  Cyclical production of antibody as a regulatory mechanism in the immune response.

Authors:  W O Weigle
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

2.  THE COMBINING REGIONS OF THE TYPE III PNEUMOCOCCUS POLYSACCHARIDE AND HOMOLOGOUS ANTIBODY.

Authors:  R G MAGE; E A KABAT
Journal:  Biochemistry       Date:  1963 Nov-Dec       Impact factor: 3.162

3.  Secondary IgG responses to type III pneumococcal polysaccharide. I. Kinetics and antigen requirements.

Authors:  H Braley-Mullen
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

4.  Inhibition of aldobiouronates in the precipitation of pneumococcal type II and III systems.

Authors:  M Heidelberger; N Roy; C P Glaudemans
Journal:  Biochemistry       Date:  1969-12       Impact factor: 3.162

5.  Quantitative studies of the specificity of anti-pneumococcal polysaccharide antibodies, types 3 and 8. I. Isolation of oligosaccharides from acid and from enzymatic hydrolysates of S3 and S8.

Authors:  J H Campbell; A M Pappenheimer
Journal:  Immunochemistry       Date:  1966-05

6.  Expression of IgG memory response in vitro to thymus-dependent and thymus-independent antigens.

Authors:  T V Tittle; M B Rittenberg
Journal:  Cell Immunol       Date:  1978-01       Impact factor: 4.868

7.  Receptors for human gamma G globulin on human neutrophils.

Authors:  R P Messner; J Jelinek
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

8.  Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.

Authors:  R Austrian
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

9.  Modulation of the immune response to lipopolysaccharide.

Authors:  J R Hiernaux; P J Baker; C Delisi; J A Rudbach
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

10.  The role of opsonins in recovery from experimental pneumococcal pneumonia.

Authors:  J C Guckian; G D Christensen; D P Fine
Journal:  J Infect Dis       Date:  1980-08       Impact factor: 5.226

View more
  16 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.

Authors:  G J Zigterman; H Snippe; M Jansze; E B Ernste; M J De Reuver; J M Willers
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

3.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

4.  A thymus-independent (type 1) phosphorylcholine antigen isolated from Trichinella spiralis protects mice against pneumococcal infection.

Authors:  P L Lim; W F Choy
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

5.  Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

Authors:  B Benaissa-Trouw; D J Lefeber; J P Kamerling; J F Vliegenthart; K Kraaijeveld; H Snippe
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

7.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

8.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

9.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.

Authors:  G J Zigterman; K Schotanus; E B Ernste; G J Van Dam; M Jansze; H Snippe; J M Willers
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

10.  Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3.

Authors:  H Snippe; J E van Dam; A J van Houte; J M Willers; J P Kamerling; J F Vliegenthart
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.